

# Feedback form

Please provide your contact details below.

Name:	Nicola Peart
If this feedback is on behalf of an organisation, please name the organisation:	No
Please provide a brief description of the organisation if applicable:	
Address/email:	Nicola.peart@otago.ac.nz
Interest in this topic (e.g. user of fertility services, health professional, researcher, member of public):	Law researcher and member of Otago University health Ethics Committee.

Please refer to page v for information about:

- Publication of feedback on ACART's website
- Official Information Act requests – possible release of you feedback
- Official Information Act requests – possible release of you name and contact details

We will acknowledge all feedback.

- ☐ I **request** that my feedback be withheld in full or part from publication on ACART's website. (If you wish a part to be withheld, please clearly indicate which part.)
- ☐ I **do not** give permission for my name to be published on ACART's website.
- ☐ I **do not** give permission for my contact details to be published on ACART's website.

If you consider that your feedback, or your name and contact details (if you are submitting on behalf of an organisation), should be withheld under the Act, please state the reasons here:

---

---

---

---

---

---

---

# Questions for response

---

## Question 1

*Refer to sections 3 and 4.*

- (a) Do you agree with ACART's assessment of the known risks and benefits to health associated with the use of cryopreserved ovarian tissue to restore ovarian function?

Yes ☒ No ☐

Please give reasons for your views.

I am no scientist, but accept the assessment that ACART has made about the risks and benefits in using cryopreserved ovarian tissue.

- (b) Are there any risks and/or benefits associated with the use of cryopreserved ovarian tissue to restore ovarian function that ACART has not identified or assessed?

Yes ☐ No ☐

If yes, please list below.

I am not aware of any, but then I am no scientist.

## Question 2

*Refer to section 4.*

- (a) Do you agree with ACART's conclusion that the risks associated with the use of cryopreserved ovarian tissue to restore ovarian function falls within a level that is acceptable in New Zealand?

Yes ☒ No ☐

Please give reasons for your views.

The main risk is that the tissue retains malignant cells that may cause cancer in women into whom the tissue is transplanted. As ACART is not recommending donation of the tissue to other women, I believe that with appropriate information about the risks to the women from whom the tissue was taken that the risk benefit balance is appropriate.

- (b) Please note any other comments below.

### Question 3

*Refer to section 4.*

- (a) Has ACART identified all the relevant areas to monitor the use of cryopreserved ovarian tissue to restore ovarian function?

Yes ☒ No ☐

Please give reasons for your views.

ACART has monitored the use of cryopreserved ovarian tissue closely and its recommendations align with the cautious approach adopted elsewhere in the world. Ongoing monitoring will be required to determine whether donation of cryopreserved tissue should be permitted

- (b) Are there any other areas ACART should monitor?

Yes ☐ No ☒

Please give reasons for your views.

## Question 4

Refer to section 5.

- (a) Has ACART identified all the ethical issues relevant to the use of cryopreserved ovarian tissue to restore ovarian function?

Yes ☒ No ☐

Please give reasons for your views.

The recommendation that cryopreserved ovarian tissue be an established procedure for women from whom the tissue was taken to restore their ovarian function aligns with ethical considerations of autonomy, beneficence and justice. The risk of relapse in malignancy from the implanted tissue appears to be small and, provided the women are fully informed, outweighed by the benefits of restoring ovarian function.

- (b) Do you agree with ACART's ethical analysis that there are no significant ethical issues associated with the use of cryopreserved ovarian tissue to restore ovarian function?

Yes ☒ No ☐

Please give reasons for your views.

See above

## Question 5

*Refer to section 6.*

- (a) Do you agree that the use of cryopreserved ovarian tissue to restore ovarian function should become an established procedure?

Yes ☒ No ☐

Please give reasons for your views.

It serves the purpose for which the tissue was cryopreserved. The risks are to the women from whom the tissue was taken and, provided they are fully informed, their autonomy should be respected.

- (b) Please note any other comments below.

## Question 6

*Refer to section 6.*

Do you agree with ACART's position that the scope for the use of cryopreserved ovarian tissue to restore ovarian function be limited to the woman from whom the tissue was excised, for her own treatment?

Yes ☒ No ☐

Please give reasons for your views.

Until there is more evidence about the risk of the tissue containing malignant cells, I support the ACART's position that donation should not be permitted.

## Question 7

*Refer to section 6.*

Do you have any further comments to share with ACART?

No. I think the document is well reasoned and the arguments are well made.